LOANS for Biomedical Research Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 5, 2024)
Long-term Opportunities for Advancing New Studies for Biomedical Research Act or the LOANS for Biomedical Research Act
This bill requires the Department of the Treasury to establish the BioBonds Program to support loans for clinical trials for eligible drugs and medical devices for unmet medical needs.
Under the program, fiscal agents purchase loans (up to $25 million per recipient) and issue collateralized bonds that are sold to investors and that are guaranteed by Treasury. An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device.
The Government Accountability Office (GAO) and Treasury must report on the program; GAO must also study whether similar programs should be established for other biomedical research projects.
What just happenedMar 8, 2024
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 5, 2024
- Mar 8, 2024Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 5, 2024IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 5, 2024IntroReferralIntro-H
Introduced in House
- Mar 5, 2024IntroReferral1000
Introduced in House